← Search & browse all drugs
CARDIOVASCULAR SYSTEM › LIPID MODIFYING AGENTS › LIPID MODIFYING AGENTS, COMBINATIONS › Lipid modifying agents in combination with other drugs
rosuvastatin and perindopril
C10BX21
Forms & Strengths
- Rosuvastatin/Perindopril arginine 5 mg/5 mg tablet
- Rosuvastatin/Perindopril arginine 5 mg/10 mg tablet
- Rosuvastatin/Perindopril arginine 10 mg/5 mg tablet
- Rosuvastatin/Perindopril arginine 10 mg/10 mg tablet
- Rosuvastatin/Perindopril arginine 20 mg/5 mg tablet
- Rosuvastatin/Perindopril arginine 20 mg/10 mg tablet
Adult Dosing
- One tablet daily, taken preferably in the morning before a meal
- Dose selection based on individual component titration
- Maximum daily dose: Rosuvastatin 20 mg / Perindopril 10 mg
- Adjust dose in severe renal impairment (CrCl < 30 mL/min)
Pediatric Dosing
- Safety and efficacy not established in pediatric patients
- Not recommended for use in children or adolescents
Indications
- Secondary prevention of cardiovascular events in patients with hypertension and/or stable coronary artery disease
- Co-administration for patients already controlled on individual monotherapy components
Mechanism of Action
- Rosuvastatin: Competitive inhibitor of HMG-CoA reductase, reducing hepatic cholesterol synthesis and upregulating LDL receptors
- Perindopril: ACE inhibitor that suppresses the renin-angiotensin-aldosterone system, causing vasodilation and reduced blood pressure
Contraindications
- Hypersensitivity to rosuvastatin, perindopril, or any ACE inhibitor
- History of angioedema related to previous ACE inhibitor therapy
- Active liver disease or unexplained persistent elevations of serum transaminases
- Pregnancy and lactation
- Concomitant use with aliskiren-containing products in patients with diabetes mellitus or renal impairment
Adverse Reactions
- Myalgia, arthralgia, and increased creatine kinase
- Persistent dry cough related to perindopril
- Headache, dizziness, and asthenia
- Hypotension, especially in volume-depleted patients
- Hyperkalemia and transient increases in serum creatinine
Drug Interactions
- Cyclosporine: Significantly increases rosuvastatin exposure
- Lithium: Perindopril may reduce lithium clearance, increasing toxicity risk
- Potassium-sparing diuretics and potassium supplements: Increase risk of severe hyperkalemia
- Antacids (aluminum/magnesium hydroxide): Decrease rosuvastatin absorption
- Coumarin anticoagulants: Rosuvastatin may enhance INR response
Curated Content: Needs Vetting Before Put to Clinical Use